Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DRA84P
|
|||
| Drug Name |
Tivanisiran
|
|||
| Drug Type |
Small interfering RNA
|
|||
| Indication | Dry eye disease [ICD-11: 9E1Z; ICD-9: 370.33] | Phase 3 | [1] | |
| Company |
Sylentis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | TRPV1 messenger RNA (TRPV1 mRNA) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04819269) Tivanisiran for Dry Eye in Subjects With Sjogren's Syndrome. U.S. National Institutes of Health. | |||
| REF 2 | Tivanisiran, a novel siRNA for the treatment of dry eye disease. Expert Opin Investig Drugs. 2018 Apr;27(4):421-426. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.